Inspira Technologies OXY B.H.N. (NASDAQ:IINN) Shares Down 10.5% – Time to Sell?

Shares of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) fell 10.5% on Thursday . The company traded as low as $1.65 and last traded at $1.70. Approximately 6,659,308 shares traded hands during trading, an increase of 1,790% from the average daily volume of 352,435 shares. The stock had previously closed at $1.90.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Inspira Technologies OXY B.H.N. in a research report on Friday, April 10th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Inspira Technologies OXY B.H.N. Stock Performance

The company has a current ratio of 1.56, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08. The firm’s 50-day moving average is $1.14 and its 200 day moving average is $0.87.

Hedge Funds Weigh In On Inspira Technologies OXY B.H.N.

A number of hedge funds have recently modified their holdings of IINN. Kestra Advisory Services LLC acquired a new stake in Inspira Technologies OXY B.H.N. in the fourth quarter valued at $71,000. Citadel Advisors LLC acquired a new position in Inspira Technologies OXY B.H.N. during the 3rd quarter worth about $105,000. Finally, Yorkville Advisors Global LP bought a new stake in shares of Inspira Technologies OXY B.H.N. in the 4th quarter valued at about $1,605,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

Inspira Technologies OXY B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.